Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/25
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial MarketsPRNewsWire • 05/01/25
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 05/01/25
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferencePRNewsWire • 03/20/25
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial MarketsPRNewsWire • 03/05/25
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia AreataPRNewsWire • 02/26/25
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes MellitusPRNewsWire • 02/24/25
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24thPRNewsWire • 02/24/25
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic DermatitisPRNewsWire • 02/10/25
Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a TurnaroundZacks Investment Research • 02/07/25
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 01/31/25
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic DermatitisPRNewsWire • 01/10/25
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH MeetingPRNewsWire • 12/07/24
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) ConvergencePRNewsWire • 11/18/24
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in FocusZacks Investment Research • 11/08/24